Back to Authors

Liu, Peiying

0000-0003-0830-5960

Mayo Clinic

Department of Diagnostic Radiology & Nuclear Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.

Citations 2

MarkVCID2 Consortium for Clinical Validation of Biomarkers of Cerebral Small Vessel Disease: Validation Framework and Baseline Characteristics
Greenberg, Steven M. , Albert, Marylin S., An, Hongyu , Arfanakis, Konstantinos , Evia, Arnold M , Caprihan, Arvind , Ford, Andria L. , Fornage, Myriam , Day, Gregory S. , Hinman, Jason D. , Kashani, Amir H. , Kramer, Joel H. , Lachner, Christian , Maillard, Pauline , Petersen, Ronald C. , Ringman, John M. , Savitz, Sean I. , Windham, B. Gwen, Zhang, Rong , Tuozzo, Carissa , Singh, Herpreet , Moy, Sue, Okey‐Ewurum, Vilma , Kivisäkk, Pia , Blacker, Deborah , Mazina, Lidiya, Helmer, Karl G. , Wruck, Lisa , Corriveau, Roderick A. , Jicha, Gregory A , Kashani, Amir H , Lachner, Christian , Lee, Jin-Moo , Liu, Peiying , Lu, Hanzhang , Maillard, Pauline , Petersen, Ronald C , Psaty, Bruce M , Ringman, John M , Rosenberg, Gary A. , Satizabal, Claudia L , Seshadri, Sudha , Vemuri, Prashanthi , Wang, Danny J J , Wilcock, Donna M , Tuozzo, Carissa , Singh, Herpreet , Okey-Ewurum, Vilma , Page, Courtney B , Mulder, Hillary , Kivisäkk, Pia , Blacker, Deborah , Mazina, Lidiya , Helmer, Karl G , Wruck, Lisa M , Day, Gregory S , Jicha, Gregory A. , Lee, Jin‐Moo , Liu, Peiying , Lu, Hanzhang , Psaty, Bruce M. , Satizábal, Claudia L. , Schneider, Julie A. , Seshadri, Sudha , Vemuri, Prashanthi , Wang, Danny J.J. , Wilcock, Donna M. , Mulder, Hillary , Schwab, Kristin

Annals of Neurology | September 22, 2025 | Volume: 99 | Issue: 2 | Pages: 449-458

10.1002/ana.78040 Get It

Objective To establish a framework for validating candidate biomarkers of cerebral small vessel diseases (SVD) associated with cognitive impairment and characterize individuals enrolled by the MarkVCID2 consortium under this framework. Methods Participants age 60 to 90 years were enrolled across 17 MarkVCID2 sites. Recruitment was targeted to enrich in cognitive symptoms (mild dementia, mild cognitive impairment, subjective cognitive decline), defined risk factors (diabetes mellitus, advanced hypertension), and Black/African American, White, and Hispanic/Latino subgroups. Enrolled participants underwent baseline visits that included cognitive testing, multimodal magnetic resonance imaging (MRI), and biofluid collection. Provisional risk for SVD‐related cognitive decline was estimated primarily by baseline cognitive symptoms plus SVD risk factors. Adjudicated risk status was estimated by cognitive symptoms plus presence of moderate‐to‐severe white matter hyperintensities, microbleeds, or lacunes on baseline MRI. Results MarkVCID2 enrolled 1883 individuals age 73.4 ± 7.5 years, 65.0% female, 24.2% Hispanic, and 27.1% non‐Hispanic Black. Among enrollees, 44.8% were provisionally designated high‐risk. After baseline MRI, 48.5% were categorized as adjudicated high‐risk status, with substantial recategorization both from low‐ to high‐risk (primarily because of MRI lesions without SVD risk factors) and high‐ to low‐risk (primarily suspected cognitive impairment at screening not confirmed by baseline testing). Interpretation MarkVCID2 baseline data indicate successful enrollment of diverse individuals enriched in factors associated with SVD‐related cognitive decline. Changes over 3 years of longitudinal follow‐up will be analyzed to validate the candidate biomarkers for 2 projected contexts of use: subject selection (identifying likelihood of future SVD progression) and study outcome (efficiently measuring SVD progression). ANN NEUROL 2026;99:449–458
Cerebrovascular reactivity MRI as a biomarker for cerebral small vessel disease–related cognitive decline: Multi‐site validation in the MarkVCID Consortium
Liu, Peiying , Hazel, Kaisha , Pottanat, George , Xu, Cuimei, Pillai, Jay J. , Lucke, Emma, Bauer, Christopher E. , Gold, Brian T. , Greenberg, Steven M. , Helmer, Karl G. , Jann, Kay , Kramer, Joel H. , Maillard, Pauline , Mulavelil, Rachel, Rodriguez, Pavel, Seshadri, Sudha , Singh, Herpreet , Dediós, Angel Gabriel Velarde, Kalyani, Rita R. , Rosenberg, Paul B. , Yaşar, Sevil , Albert, Marilyn , Lu, Hanzhang , Lu, Hanzhang , Seshadri, Sudha , Pillai, Jay J , Liu, Peiying , Maillard, Pauline , Lin, Zixuan , Jiang, Dengrong , Jicha, Gregory A. , Satizábal, Claudia L. , Schwab, Kristin , Wang, Danny J.J. , Moghekar, Abhay

Alzheimer's & Dementia | July 1, 2024 | Volume: 20 | Issue: 8 | Pages: 5281-5289

10.1002/alz.13888 Get It

Abstract INTRODUCTION Vascular contributions to cognitive impairment and dementia (VCID) represent a major factor in cognitive decline in older adults. The present study examined the relationship between cerebrovascular reactivity (CVR) measured by magnetic resonance imaging (MRI) and cognitive function in a multi‐site study, using a predefined hypothesis. METHODS We conducted the study in a total of three analysis sites and 263 subjects. Each site performed an identical CVR MRI procedure using 5% carbon dioxide inhalation. A global cognitive measure of Montreal Cognitive Assessment (MoCA) and an executive function measure of item response theory (IRT) score were used as outcomes. RESULTS CVR and MoCA were positively associated, and this relationship was reproduced at all analysis sites. CVR was found to be positively associated with executive function. DISCUSSION The predefined hypothesis on the association between CVR and a global cognitive score was validated in three independent analysis sites, providing support for CVR as a biomarker in VCID. Highlights This study measured a novel functional index of small arteries referred to as cerebrovascular reactivity (CVR). CVR was positively associated with global cognition in older adults. This finding was observed in three independent cohorts at three sites. Our statistical analysis plan was predefined before beginning data collection.